WO2012073508A1 - 湿潤結晶を使用したマレイン酸塩の製造方法 - Google Patents
湿潤結晶を使用したマレイン酸塩の製造方法 Download PDFInfo
- Publication number
- WO2012073508A1 WO2012073508A1 PCT/JP2011/006704 JP2011006704W WO2012073508A1 WO 2012073508 A1 WO2012073508 A1 WO 2012073508A1 JP 2011006704 W JP2011006704 W JP 2011006704W WO 2012073508 A1 WO2012073508 A1 WO 2012073508A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- compound represented
- crystal
- represented
- Prior art date
Links
- 0 CCC(C(*O)=C(C1C)N=*CC=CC=NCN(CC2)C[C@]2NC)=CC1OC Chemical compound CCC(C(*O)=C(C1C)N=*CC=CC=NCN(CC2)C[C@]2NC)=CC1OC 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
Definitions
- the present invention relates to a method for producing maleate using a wet crystal of a benz [d] [1,3] oxazine derivative.
- Human neutrophil elastase is a kind of serine hydrolase released from neutrophil granules that appear in the case of infection or inflammatory disease.
- Neutrophil elastase is an enzyme that hydrolyzes elastin, collagen, proteoglycan, fibronectin or other proteins that constitute the stroma of connective tissues in the body such as lung, cartilage, blood vessel wall, and skin. Furthermore, it has been shown that neutrophil elastase acts on other proteins or cells.
- serine hydrolase such as neutrophil elastase maintains the homeostasis of the living body.
- the activity of serine hydrolase is also controlled by endogenous proteinaceous inhibitors such as ⁇ 1-protease inhibitors, ⁇ 2-macroglobulins or secretory leukocyte protease inhibitors.
- endogenous proteinaceous inhibitors such as ⁇ 1-protease inhibitors, ⁇ 2-macroglobulins or secretory leukocyte protease inhibitors.
- Serine hydrolases Diseases involving serine hydrolase include emphysema, acute respiratory distress syndrome, adult respiratory distress syndrome (ARDS), idiopathic interstitial pneumonia (IIP), cystic pulmonary fibrosis, chronic interstitial pneumonia, chronic bronchitis, Chronic airway infection, diffuse panbronchiolitis, bronchiectasis, asthma, pancreatitis, nephritis, liver failure, rheumatoid arthritis, arthrosclerosis, osteoarthritis, psoriasis, periodontitis, atherosclerosis, organ transplantation Rejection, early rupture, blistering, shock, sepsis, systemic lupus erythematosus (SLE), Crohn's disease, disseminated intracapillary coagulation syndrome (DIC), tissue damage after ischemia-reperfusion, formation of corneal scar tissue , Myelitis and the like, and the development of serine hydrolase inhibitors as therapeutic agents for these diseases is expected.
- the benz [d] [1,3] oxazine derivative described in Patent Document 1 is excellent in serine hydrolase inhibitory activity, it is low in stability during long-term storage, etc. Further, a compound having excellent physical properties was desired.
- the present inventors have found a maleate salt of a benz [d] [1,3] oxazine derivative as a compound having excellent drug substance stability, solubility and crystallinity (International Application No. PCT / JP2010). / 005786).
- the maleate can be produced via a free form (compound (2)).
- the free body obtained so far is an amorphous solid and it is essential to concentrate the free body solution after column purification and column purification, it is not preferable as an industrial production method.
- the concentrate of the free body solution is a glassy solid, it has various manufacturing problems (manufacturing costs, repurification, storage, transportation, weighing, etc.).
- the inventors have obtained a free form of the benz [d] [1,3] oxazine derivative.
- the present invention has been found that the maleate of benz [d] [1,3] oxazine is crystallized by simple operation from crystallization in acetone-water to obtain wet crystals, and from free wet crystals. Was completed.
- the gist of the present invention is as follows. 1) Formula (3) In the presence of a base, the compound represented by formula (4) By reacting with a compound represented by formula (2) To obtain a compound represented by By mixing the obtained compound represented by the formula (2) with acetone and water, crystals of the compound represented by the formula (2) are precipitated, By adding maleic acid to the solution of the compound represented by the above formula (2) prepared by dissolving the obtained crystal of the compound represented by the above formula (2) directly or after being dried in a solvent. , Formula (1) The manufacturing method of the maleate crystal
- a solution of the compound represented by the above formula (2) is prepared by dissolving crystals of the compound represented by the above formula (2) in a solvent after drying, Crystals of the compound represented by the above formula (2) are dried by drying under reduced pressure or by dissolving in water and a solvent that separates into two layers, and then removing the free water and concentrating.
- a solution of the compound represented by the formula (2) is prepared by dissolving crystals of the compound represented by the formula (2) in a solvent after drying, Crystals of the compound represented by the above formula (2) are dried by drying under reduced pressure or by dissolving in water and a solvent that separates into two layers, and then removing the free water and concentrating.
- the compound represented by the formula (1) which is a drug substance having excellent stability, solubility and crystallinity, is provided with high purity and efficiency (without performing column purification). Became possible.
- the present invention is directed to a maleate salt represented by the formula (1) (hereinafter referred to as “maleic acid salt”) (hereinafter referred to as “compound (2)”). , which may be abbreviated as compound (1)).
- Compound (1) which is an object of the production method of the present invention, is 2- [2-((S) -3-dimethylaminopyrrolidin-1-yl) pyridin-3-yl] -5-ethyl-7-methoxy. -4H-Benz [d] [1,3] oxazin-4-one maleate with excellent solubility, stability, and excellent crystallinity under certain conditions. Furthermore, since the compound (1) does not have adhering water and does not increase / decrease in weight due to moisture absorption / release, the compound (1) is excellent in handleability. On the other hand, since the compound (2), which is a production intermediate of the compound (1), has been obtained as a glassy solid until now, column purification has been essential.
- the present inventor has found that compound (2) crystallizes under certain conditions.
- the diffraction angle (2 ⁇ ⁇ 0.5 °) is 8.02 °
- 12. 3 shows powder X-ray diffraction patterns having peaks at 0 °, 15.4 °, 24.2 °, and 24.7 °.
- the crystal has a characteristic powder X-ray diffraction peak that is distinguishable from other crystals at a diffraction angle (2 ⁇ ⁇ 0.5 °) of 15.4 °.
- the crystal of the compound (2) has excellent physical properties in terms of crystal state, crystal properties and stability, compared to amorphous.
- Compound (2) is, for example, a compound represented by formula (4) (hereinafter referred to as compound (3)) in the presence of a base represented by formula (3) (hereinafter sometimes abbreviated as compound (3)). (It may be abbreviated as (4)))).
- the base used in this reaction is not particularly limited, but a lower alkylamine such as triethylamine is preferable.
- the solvent to be used is not particularly limited as long as it is a solvent that does not participate in the reaction, and examples thereof include hydrophilic solvents such as dimethylformamide. Further, the amount of the solvent used is not particularly limited. However, since the reaction proceeds smoothly, the solvent is preferably used in an amount of 5 to 15 times, more preferably 7 times the amount of the compound represented by the formula (3). .
- this reaction is not particularly limited, it is preferably carried out at 10 to 40 ° C., more preferably 30 ° C., because the reaction proceeds smoothly.
- using 10 times the amount of the solvent relative to the compound means using 10 mL of the solvent relative to 1 g of the compound.
- acetone By mixing the compound (2) produced by the above method with acetone and water, crystals of the compound (2) can be precipitated.
- a reaction solution containing the compound (2) produced by the reaction between the compound (3) and the compound (4) is mixed with acetone and water, or the compound described in WO2008 / 036379 ( It can be performed by mixing the acetone solution of the column purified product of 2) with water.
- acetone can be used in an amount of 5 to 15 times the amount of the compound represented by the formula (3), for example, but preferably 9 times the amount.
- the amount of water to be crystallized can be 15 to 35 times the amount of the compound represented by formula (3), for example, but 25 times is preferred.
- Acetone and water can be mixed with the reaction solution at 0 to 30 ° C., for example, but 10 ° C. is preferable.
- the obtained crystal of the compound (2) can be used in a reaction for producing the compound (1) as the next reaction.
- the obtained crystal of the compound (2) is separated from the reaction liquid in which acetone and water are mixed, for example, by filtration, and then used as it is (directly) or after drying and used in the next reaction. it can.
- the crystals of compound (2) can be stored in a wet state, and after storage, the crystals of compound (2) can be used directly or dried for the next reaction.
- the term “directly” means that no drying treatment is performed on the crystals of the compound (2).
- the wet crystals preferably contain 30 to 70 w / w%, more preferably 40 to 60 w / w% of water.
- the obtained crystals can be further recrystallized with acetone and water to obtain crystals with higher chemical purity.
- acetone used for recrystallization can be used in an amount of 10 to 20 times, for example, 15 times the amount of the dried compound (2).
- the amount of water to be crystallized can be 20 to 40 times the amount of the dried compound (2), but 30 times is preferred.
- Compound (1) can be produced using a solvent in which compound (2), maleic acid, and compound (2) are dissolved.
- compound (1) can be produced by adding maleic acid to a solution of compound (2).
- the solution of the compound (2) can be prepared by dissolving the crystal of the compound (2) obtained by mixing the compound (2) with acetone and water, directly or after drying, in a solvent. it can. Among these, it is preferable to melt
- drying means not only drying under reduced pressure but also mixing of the above compound (2) with acetone and water in a solvent that separates into water and two layers (for example, ethyl acetate, toluene, methylene chloride, chloroform, etc.). It includes those obtained by dissolving the crystals of the obtained compound (2) and then removing the free water and concentrating. Concentration after removing the free water is performed by, for example, drying using a desiccant such as anhydrous sodium sulfate and then concentrating, or concentrating the solution as it is without using the desiccant. It may be.
- a desiccant such as anhydrous sodium sulfate
- an aprotic organic solvent such as acetonitrile, ethyl acetate, acetone, tetrahydrofuran is desirable. In particular, acetone is more desirable.
- a diluent solvent may be further added to the suspension of the crystalline solid from which the compound (1) has crystallized.
- a diluting solvent ethyl acetate, t-butyl methyl ether, tetrahydrofuran, diethyl ether, or diisopropyl ether is desirable. In particular, ethyl acetate, t-butyl methyl ether, or diisopropyl ether is more desirable.
- the obtained compound (1) can be further recrystallized using a suitable solvent.
- a suitable solvent As the solvent used for recrystallization, acetone, tetrahydrofuran, acetonitrile, 1,2-dimethoxyethane, ethyl acetate, and water can be used alone or in combination, but an acetone-water mixed solvent is preferable.
- Dilution ether added to precipitate crystals includes diisopropyl ether, ethyl acetate, or t-butyl methyl ether.
- N, N-dimethylformamide (65 mL) and triethylamine (11.1 mL) were added to compound (3) (10.0 g) to give a suspension.
- Compound (4) (5.14 g) was added dropwise to the suspension under cooling and stirring. The mixture was washed with N, N-dimethylformamide (5 mL), stirred at an internal temperature of 8 to 17 ° C. for 2 hours, and then allowed to stand overnight at room temperature to obtain a uniform reaction solution (87.7 g). Half of the reaction solution (43.8 g) was cooled and stirred, acetone (35 mL) was added, and the internal temperature was cooled to 9 ° C.
- the precipitated crystals were collected by filtration, washed with a mixed solution of diisopropyl ether (40.0 mL) and acetone (40.0 mL), and then wet crude crystals (14.2 g) of the resulting compound (1) were blown dry at 50 ° C.
- crude crystals (13.4 g) of compound (1) were obtained as white powder and lump.
- Acetone (200 mL) and purified water (10.0 mL) were added to the resulting crude crystal (10.0 g) of compound (1) and dissolved under heating and stirring.
- the obtained compound (1) solution was filtered, the container was washed with a mixture of acetone (30.0 mL) and purified water (1.50 mL), and the filtrate was heated and stirred.
- Diisopropyl ether 250 mL was added dropwise to the filtrate at an internal temperature of 43 to 45 ° C. for crystallization, and then stirred at an internal temperature of 43 to 46 ° C. for 10 minutes, then cooled and cooled to an internal temperature of 6 to 15 ° C. Stir for 30 minutes.
- the precipitated crystals were collected by filtration, washed with a mixture of diisopropyl ether (40.0 mL) and acetone (40.0 mL), and then wet crystals (9.28 g) of the obtained compound (1) were blown and dried at 50 ° C.
- Compound (1) (8.80 g) was obtained as a white powder and lump with a yield of 69.5%.
- the precipitated crystals were collected by filtration and washed with a mixed solution of acetone (10.0 mL) and normal water (100 mL) to obtain a recrystallized wet product (26.1 g) of compound (2) as a white lump.
- the obtained recrystallized wet product (26.1 g) of compound (2) was dissolved in ethyl acetate (200 mL), the organic layer was separated and concentrated under reduced pressure, and the resulting concentrate was further diluted with ethyl acetate (200 mL). ) was added and dissolved, followed by concentration under reduced pressure to obtain a concentrate (12.5 g) of compound (2) as a yellow oil.
- the resulting concentrate (12.5 g) of compound (2) was dissolved in acetone (230 mL) to obtain a solution of compound (2).
- a solution of maleic acid (3.87 g) in acetone (50.0 mL) was added dropwise to the solution with stirring at an internal temperature of 36 ° C. to crystallize the compound (1).
- the container was washed with acetone (20.0 mL), and then diisopropyl ether (300 mL) was added dropwise.
- the suspension of compound (1) was heated and stirred at an internal temperature of 45 to 47 ° C. for 10 minutes, then cooled, and stirred at an internal temperature of 8 to 15 ° C. for 30 minutes.
- the precipitated crystals were collected by filtration, washed with a mixed solution of diisopropyl ether (40.0 mL) and acetone (40.0 mL), and then wet crude crystals (15.2 g) of the resulting compound (1) were blown dry at 50 ° C.
- crude crystals (12.7 g) of compound (1) were obtained as white powder and lump.
- Acetone (200 mL) and purified water (10.0 mL) were added to the resulting crude crystal (10.0 g) of compound (1) and dissolved under heating and stirring.
- the obtained compound (1) solution was filtered, the container was washed with a mixture of acetone (30.0 mL) and purified water (1.50 mL), and the filtrate was heated and stirred.
- Diisopropyl ether 250 mL was added dropwise to the filtrate at an internal temperature of 43 to 45 ° C. to crystallize Compound (1), and then the mixture was stirred at an internal temperature of 44 to 45 ° C. for 10 minutes, then cooled and cooled to the internal temperature. Stir at 6-15 ° C. for 30 minutes. The precipitated crystals were collected by filtration, washed with a mixture of diisopropyl ether (40.0 mL) and acetone (40.0 mL), and then wet crystals (9.31 g) of the obtained compound (1) were blown and dried at 50 ° C. Compound (1) (8.83 g) was obtained as a white powder and lump in a yield of 65.9%.
- Crystal (20.0 g, mixture of high and low melting point crystals) of compound (1) described in application number PCT / JP2010 / 005786 was mixed with ethyl acetate (300 mL) and sodium bicarbonate (20.0 g) and normal water (300 mL) was sequentially added, and the compound (1) was dissolved under stirring at an internal temperature of 16 to 17 ° C.
- the compound (1) solution was stirred at an internal temperature of 13 to 18 ° C. for 20 minutes to obtain a compound (2).
- an organic layer containing the compound (2) was separated, and the obtained organic layer was separated into hydrogen carbonate. Washed with a solution of sodium (6.00 g) and normal water (100 mL).
- powder X-ray diffraction The result of the powder X-ray diffraction of the wet crystal of compound (2) (Example 1) is shown in FIG. From the results of powder X-ray diffraction, it was confirmed that the wet crystals were crystalline powders and lumps. The measurement conditions for powder X-ray diffraction are shown below.
- Powder X-ray diffraction The specimen was filled into a filling portion of a flat plate sample holder made of glass, and the powder X-ray diffraction of the specimen was measured using a Rigaku Denki RINT2200 type powder X-ray diffractometer.
- Tube current 36 mA
- Tube voltage 40 kV
- Wavelength 1.5405 mm (K ⁇ 1), 1.5443 mm (K ⁇ 2), 1.3922 mm (K ⁇ 1)
- Divergent slit 1 °
- Receiving slit 0.15 mm
- Scattering slit 1 °
- Counter cathode Copper scanning range: 5-40 °
- Test Example 2 X-ray powder diffraction after drying compound (2) wet crystals
- Example 2 The wet crystal of compound (2) (Example 1) is filled in the flat plate sample holder used in Test Example 1, dried in a silica gel (blue) desiccator to obtain a dry product of compound (2), and then powder X-ray When diffraction was measured by the method of Test Example 1, an amorphous diffraction pattern as shown in FIG. 2 was observed.
- Test Example 3 Stability test of compound (2) (powder X-ray diffraction)
- Example 2 The compound (2) wet crystals (Example 1) and the dried product (Reference Example 1) were each sealed in a brown bottle and stored at 25 ° C. for 2 weeks and 4 weeks, respectively.
- the results of measuring the powder X-ray diffraction of each specimen after storage by the method of Test Example 1 are shown in FIGS.
- the dried product of compound (2) was completely amorphous, but wet crystals of compound (2) did not change in the crystalline state.
- HPLC measurement method HPLC column: InertsilODS-3V (4.6 mmID ⁇ 150 mm, particle size 5 ⁇ m) Measurement wavelength: 240 nm Column temperature: 35 ° C Flow rate: 1.0 mL / min
- Mobile phase A Dissolved sodium 1-octanesulfonate (1.08 g) in diluted phosphoric acid (1 ⁇ 1000) to 1000 mL
- Mobile phase B Acetonitrile solution for liquid chromatography
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
優れたセリンヒドロラーゼ阻害剤としては、ベンズ[d][1,3]オキサジン誘導体の報告がある(特許文献1)。
該マレイン酸塩は、フリー体(化合物(2))を経由して製造することができる。しかし、これまで得られたフリー体は、アモルファス状固体であり、カラム精製とカラム精製後のフリー体溶液の濃縮が必須であるため、工業的製造方法として好ましいものではなかった。さらに、フリー体溶液の濃縮物は、ガラス状の固形物であるため、製造上様々な課題(製造コスト、再精製、保管、運搬、および秤量など)を有していた。
1) 式(3)
得られた上記式(2)で表される化合物とアセトンおよび水とを混和することにより、上記式(2)で表される化合物の結晶を析出させ、
得られた上記式(2)で表される化合物の結晶を直接、若しくは乾燥後溶媒に溶解させることにより調製された上記式(2)で表される化合物の溶液にマレイン酸を添加することにより、式(1)
上記式(2)で表される化合物の結晶は、減圧乾燥、または水と二層に分離する溶媒に溶解後、遊離する水を除去し、濃縮することにより乾燥される、上記式(1)で表されるマレイン酸塩の結晶の製造方法。
得られた上記式(2)で表される化合物の溶液にマレイン酸を添加することにより、式(1)
上記式(2)で表される化合物の結晶は、減圧乾燥、または水と二層に分離する溶媒に溶解後、遊離する水を除去し、濃縮することにより乾燥される、上記式(1)で表されるマレイン酸塩の結晶の製造方法。
一方、化合物(1)の製造中間体である化合物(2)は、これまでガラス状固形物として得られていたため、カラム精製が必須であった。しかし、本発明者により、化合物(2)が特定の条件下において結晶化することが見出された。本発明者により見出された化合物(2)の結晶は、銅放射線を用いて測定したとき、例えば図1のように、回折角(2θ±0.5°)として8.02°、12.0°、15.4°、24.2°、および24.7°にピークを有する粉末X線回折図形を示す。特に、当該結晶は、回折角(2θ±0.5°)として15.4°に、他の結晶と識別可能である特徴的な粉末X線回折ピークを有する。化合物(2)の結晶は、アモルファスに比べて、結晶状態、結晶の性状および安定性において優れた物性を有する。
当該混和は、例えば化合物(3)と化合物(4)との反応により生成された化合物(2)が含まれている反応液とアセトンおよび水を混和させるか、又はWO2008/036379に記載の化合物(2)のカラム精製品のアセトン溶液と水を混和させることで行うことができる。この時、アセトンは例えば式(3)で表される化合物に対し5~15倍量を用いることができるが、9倍量が好ましい。結晶化させる水は例えば式(3)で表される化合物に対し15~35倍量を用いることができるが、25倍量が好ましい。
アセトンおよび水は、例えば0~30℃で反応液と混和することができるが、10℃が好ましい。
得られた化合物(2)の結晶は、次反応である化合物(1)を生成するための反応に用いることができる。ここで、得られた化合物(2)の結晶は、例えばろ取により上述のアセトンおよび水が混和された反応液から分離された後、そのまま(直接)あるいは乾燥後、次反応に使用することもできる。また、化合物(2)の結晶を湿潤状態において保存し、保存後に、化合物(2)の結晶を直接または乾燥して次反応に用いることもできる。
本明細書において、直接とは、化合物(2)の結晶に対して乾燥処理を行わないことをいう。
なお、化合物(2)の湿潤結晶を安定に保存させるためには、当該湿潤結晶中、水を30~70w/w%、さらに好ましくは40~60w/w%含有することが好ましい。
また、得られた結晶は、さらにアセトンと水で再結晶することにより、より化学純度の高い結晶を得ることも可能である。この時、再結晶に用いるアセトンは、乾燥させた化合物(2)に対し、例えば10~20倍量を用いることができるが、15倍量が好ましい。結晶化させる水は乾燥させた化合物(2)に対し20~40倍量を用いることができるが、30倍量が好ましい。
当該製造において用いられる溶媒としては、アセトニトリル、酢酸エチル、アセトン、テトラヒドロフラン、などの非プロトン性有機溶媒が望ましい。特に、アセトンがより望ましい。化合物(1)が晶析した結晶性固体の懸濁液には、さらに希釈溶媒を加えてもよい。希釈溶媒としては、酢酸エチル、t-ブチルメチルエーテル、テトラヒドロフラン、ジエチルエーテル、またはジイソプロピルエーテルが望ましい。特に、酢酸エチル、t-ブチルメチルエーテル、またはジイソプロピルエーテルがより望ましい。
実施例1 化合物(2)の湿潤結晶の合成方法
反応液の半量(43.8 g)を冷却撹拌し、アセトン(35 mL)を加え内温9℃に冷却した。常水(175 mL)を内温9~22℃で反応液とアセトンの混液にゆっくり滴下して結晶を析出させ、その後、内温7~13℃で1時間20分撹拌した。析出結晶をろ取し、アセトン(10 mL)と常水(40 mL)の混液で析出結晶を洗浄して、白色粉末及び塊として化合物(2)の湿潤結晶(9.55 g)を得た。
実施例2 化合物(2)の湿潤結晶を経由した化合物(1)の合成方法
得られた化合物(2)の湿潤結晶(26.6 g)を酢酸エチル(200 mL)に溶解後、有機層を分取して減圧濃縮し、さらに得られた濃縮物に酢酸エチル(200 mL)を加え溶解した後、減圧濃縮して黄色油状物として化合物(2)の濃縮物(13.7 g)を得た。
得られた化合物(2)の濃縮物(13.7 g)をアセトン(230 mL)に溶解し、化合物(2)の溶液とした。加熱撹拌下、当該溶液に内温36~37℃でマレイン酸(3.87 g)のアセトン(50.0 mL)溶液を滴下して化合物(1)を晶析させ、アセトン(20.0 mL)で容器を洗い込み、その後、ジイソプロピルエーテル(300 mL)を滴下した。次いで、化合物(1)の懸濁液を内温45~46℃で10分間加熱撹拌した後、冷却し、内温7~15℃で30分間撹拌した。析出結晶をろ取し、ジイソプロピルエーテル(40.0 mL)とアセトン(40.0 mL)の混液で析出結晶を洗浄後、得られた化合物(1)の粗結晶湿潤品(14.2 g)を50℃で送風乾燥して、白色粉末及び塊として化合物(1)の粗結晶(13.4 g)を得た。
得られた化合物(1)の粗結晶(10.0 g)にアセトン(200 mL)と精製水(10.0 mL)を加え加熱撹拌下、溶解した。得られた化合物(1)溶液をろ過し、アセトン(30.0 mL)と精製水(1.50 mL)の混液で容器を洗い込み、ろ液を加熱撹拌した。当該ろ液に内温43~45℃でジイソプロピルエーテル(250 mL)を滴下して晶析させ、その後、内温43~46℃で10分間撹拌した後、冷却し、内温6~15℃で30分間撹拌した。析出結晶をろ取し、ジイソプロピルエーテル(40.0 mL)とアセトン(40.0 mL)の混液で析出結晶を洗浄後、得られた化合物(1)の湿潤結晶(9.28 g)を50℃で送風乾燥して、白色粉末及び塊として化合物(1)(8.80 g)を収率69.5%で得た。
融点(熱板法):157~163℃.
元素分析計算値 C22H26N4O3・C4H4O4 (MW:510.54):C,61.17%;H,5.92%;N,10.97%.元素分析実測値:C,61.09%;H,5.91%;N,10.95%.
ESI(posi)-MS m/z:395[(C22H26N4O3 + H)+].
1H-NMR(400 MHz,DMSO-d6)δ:1.22(3H,t,J = 7.6 Hz),2.02-2.12(1H,m),2.29-2.36(1H,m),2.78(6H,s),3.07-3.20(2H,m),3.44-3.53(2H,m),3.68(1H,dd,J = 11.5 Hz,7.3 Hz),3.76(1H,dd,J = 11.5 Hz,6.8 Hz),3.83-3.96(1H,m),3.92(3H,s),6.03(2H,s),6.91(1H,dd,J = 7.8 Hz,4.9 Hz),7.02(1H,d,J = 2.4 Hz),7.04(1H,d,J = 2.4 Hz),8.05(1H,dd,J = 7.6 Hz,2.0 Hz),8.34(1H,dd,J = 4.6 Hz,1.7 Hz).
実施例3 化合物(2)の再結晶精製品を用いた化合物(1)の合成方法
得られた化合物(2)の粗結晶湿潤品(25.8 g)にアセトン(200 mL)を加え撹拌下溶解し、冷却した。得られた化合物(2)のアセトン溶液に内温8~13℃で常水(400 mL)をゆっくり滴下して化合物(2)を晶析させ、その後、内温8~9℃で30分間撹拌した。析出結晶をろ取し、アセトン(10.0 mL)と常水(100 mL)の混液で析出結晶を洗浄後、白色塊として化合物(2)の再結晶湿潤品(26.1 g)を得た。
得られた化合物(2)の再結晶湿潤品(26.1 g)を酢酸エチル(200 mL)に溶解後、有機層を分取して減圧濃縮し、さらに得られた濃縮物に酢酸エチル(200 mL)を加え溶解した後、減圧濃縮し黄色油状物として化合物(2)の濃縮物(12.5 g)を得た。
得られた化合物(2)の濃縮物(12.5 g)をアセトン(230 mL)に溶解し、化合物(2)の溶液とした。当該溶液に、加熱撹拌下、内温36℃でマレイン酸(3.87g)のアセトン(50.0 mL)溶液を滴下して化合物(1)を晶析させた。アセトン(20.0 mL)で容器を洗い込み、その後,ジイソプロピルエーテル(300 mL)を滴下した。次いで、化合物(1)の懸濁液を、内温45~47℃で10分間加熱撹拌した後、冷却し、内温8~15℃で30分間撹拌した。析出結晶をろ取し、ジイソプロピルエーテル(40.0 mL)とアセトン(40.0 mL)の混液で析出結晶を洗浄後、得られた化合物(1)の粗結晶湿潤品(15.2 g)を50℃で送風乾燥して、白色粉末及び塊として化合物(1)の粗結晶(12.7 g)を得た。
得られた化合物(1)の粗結晶(10.0 g)にアセトン(200 mL)と精製水(10.0 mL)を加え加熱撹拌下、溶解した。得られた化合物(1)溶液をろ過し、アセトン(30.0 mL)と精製水(1.50 mL)の混液で容器を洗い込み、ろ液を加熱撹拌した。当該ろ液に内温43~45℃でジイソプロピルエーテル(250 mL)を滴下して化合物(1)を晶析させ、その後、内温44~45℃で10分間撹拌した後、冷却し、内温6~15℃で30分間撹拌した。析出結晶をろ取し、ジイソプロピルエーテル(40.0 mL)とアセトン(40.0 mL)の混液で析出結晶を洗浄後、得られた化合物(1)の湿潤結晶(9.31 g)を50℃で送風乾燥して、白色粉末及び塊として化合物(1)(8.83 g)を収率65.9%で得た。
融点(熱板法):164~165℃.
元素分析計算値 C22H26N4O3・C4H4O4 (MW:510.54):C,61.17%;H,5.92%;N,10.97%.元素分析実測値:C,61.07%;H,5.87%;N,10.96%.
ESI(posi)-MS m/z:395[(C22H26N4O3 + H)+].
1H-NMR(400 MHz,DMSO-d6)δ:1.22(3H,t,J = 7.3 Hz),2.02-2.12(1H,m),2.29-2.36(1H,m),2.78(6H,s),3.09-3.18(2H,m),3.45-3.52(2H,m),3.68(1H,dd,J = 11.7 Hz,7.3 Hz),3.76(1H,dd,J = 11.7 Hz,7.1 Hz),3.83-3.95(1H,m),3.92(3H,s),6.03(2H,s),6.91(1H,dd,J = 7.6 Hz,4.6 Hz),7.02(1H,d,J = 2.7 Hz),7.04(1H,d,J = 2.7 Hz),8.05(1H,dd,J = 7.8 Hz,2.0 Hz),8.34(1H,dd,J = 4.6 Hz,2.0 Hz).
実施例4 化合物(1)からの化合物(2)の湿潤結晶の製造方法
得られた化合物(2)(17.7 g)にアセトン(177 mL)を加え溶解した。化合物(2)の溶液に、撹拌下、常水(472 mL)を内温17~33℃でゆっくり滴下して化合物(2)を晶析させ、その後、内温8~15℃で30分間冷却撹拌した。析出結晶をろ取し、アセトン(11.8 mL)と常水(59.0 mL)の混液で析出結晶を洗浄して、帯黄白色塊として化合物(2)の湿潤結晶(32.7 g)を得た。
参考例1 化合物(2)の湿潤結晶の乾燥方法
実施例4により得られた化合物(2)の湿潤結晶を室温下で減圧乾燥し、淡黄色粉末として化合物(2)の乾燥品(14.6 g)を収率93.4%で得た。
融点(熱板法):48℃よりガラス転移
水分(カールフィッシャー):1.32%
1H-NMR(CDCl3)δ:1.30(3H,t,J = 7.6 Hz),1.80-1.88(1H,m),2.08-2.15(1H,m),2.25(6H,s),2.72-2.80(1H,m),3.15-3.28(2H,m),3.43-3.56(3H,m),3.66(1H,dt,J = 6.6 Hz,10.7 Hz),3.92(3H,s),6.72(1H,dd,J = 7.8 Hz,4.9 Hz),6.88(1H,d,J = 2.7 Hz),6.95(1H,d,J = 2.7 Hz),8.00(1H,dd,J = 7.8 Hz,2.0 Hz),8.30(1H,dd,J = 4.9 Hz,2.0 Hz).
ESI-MS(posi) m/z:395(M+1)+
元素分析 Calcd for C22H26N4O3:C,66.99;H,6.64;N,14.20. Found:C,65.89;H,6.66;N,13.96.
試験例1 化合物(2)の湿潤結晶のX線回折
粉末X線回折:
検体をガラス製の平板試料ホルダーの充填部に充填し、理学電機RINT2200型粉末X線回折装置を用いて検体の粉末X線回折を測定した。
測定条件
管電流:36 mA
管電圧:40 kV
走査速度:毎分2°
波長:1.5405Å(Kα1),1.5443Å(Kα2),1.3922Å(Kβ1)
発散スリット:1°
受光スリット:0.15 mm
散乱スリット:1°
対陰極:銅
走査範囲:5~40°
試験例2 化合物(2)湿潤結晶の乾燥後の粉末X線回折
試験例3 化合物(2)の安定性試験(粉末X線回折)
試験例4 化合物(2)の安定性試験(性状)
化合物(2)の乾燥品(参考例1)の性状
試験例5
HPLC測定方法:
HPLCカラム:InertsilODS-3V(4.6 mmID × 150 mm, 粒子径 5 μm)
測定波長:240 nm
カラム温度:35℃
流量:1.0 mL/分
移動相A:1-オクタンスルホン酸ナトリウム(1.08g)を薄めたリン酸(1 → 1000)に溶かし1000mLとした液
ここで、薄めたリン酸(1 → 1000)とは、リン酸1mLを水に溶解し1000mLとした意味である。
移動相B:液体クロマトグラフィー用アセトニトリル
送液条件
Claims (6)
- 前記式(2)で表される化合物の溶液が、前記式(2)で表される化合物の結晶を乾燥後、溶媒に溶解させることにより調製され、
前記式(2)で表される化合物の結晶は、減圧乾燥、または水と二層に分離する溶媒に溶解後、遊離する水を除去し、濃縮することにより乾燥される、請求項1に記載の前記式(1)で表されるマレイン酸塩の結晶の製造方法。 - 前記式(2)で表される化合物の溶液が、前記式(2)で表される化合物の結晶を乾燥後、溶媒に溶解させることにより調製され、
前記式(2)で表される化合物の結晶は、減圧乾燥、または水と二層に分離する溶媒に溶解後、遊離する水を除去し、濃縮することにより乾燥される、請求項5に記載の前記式(1)で表されるマレイン酸塩の結晶の製造方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/990,380 US20130317214A1 (en) | 2010-11-30 | 2011-11-30 | Method for producing maleate using wet crystal |
CA2819375A CA2819375A1 (en) | 2010-11-30 | 2011-11-30 | Method for producing maleate using wet crystal |
EP11845985.8A EP2647636A4 (en) | 2010-11-30 | 2011-11-30 | PROCESS FOR PRODUCTION OF MALATEATE USING WET CRYSTALS |
JP2012546703A JPWO2012073508A1 (ja) | 2010-11-30 | 2011-11-30 | 湿潤結晶を使用したマレイン酸塩の製造方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010266686 | 2010-11-30 | ||
JP2010-266686 | 2010-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012073508A1 true WO2012073508A1 (ja) | 2012-06-07 |
Family
ID=46171470
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/006704 WO2012073508A1 (ja) | 2010-11-30 | 2011-11-30 | 湿潤結晶を使用したマレイン酸塩の製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20130317214A1 (ja) |
EP (1) | EP2647636A4 (ja) |
JP (1) | JPWO2012073508A1 (ja) |
CA (1) | CA2819375A1 (ja) |
WO (1) | WO2012073508A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008036379A2 (en) | 2006-09-21 | 2008-03-27 | Activx Biosciences, Inc. | Serine hydrolase inhibitors |
WO2011036895A1 (ja) * | 2009-09-25 | 2011-03-31 | 杏林製薬株式会社 | マレイン酸塩およびその結晶 |
-
2011
- 2011-11-30 US US13/990,380 patent/US20130317214A1/en not_active Abandoned
- 2011-11-30 EP EP11845985.8A patent/EP2647636A4/en not_active Withdrawn
- 2011-11-30 WO PCT/JP2011/006704 patent/WO2012073508A1/ja active Application Filing
- 2011-11-30 JP JP2012546703A patent/JPWO2012073508A1/ja active Pending
- 2011-11-30 CA CA2819375A patent/CA2819375A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008036379A2 (en) | 2006-09-21 | 2008-03-27 | Activx Biosciences, Inc. | Serine hydrolase inhibitors |
JP2010504334A (ja) * | 2006-09-21 | 2010-02-12 | アクティヴィックス バイオサイエンシーズ インコーポレイテッド | セリンヒドロラーゼ阻害剤 |
WO2011036895A1 (ja) * | 2009-09-25 | 2011-03-31 | 杏林製薬株式会社 | マレイン酸塩およびその結晶 |
Non-Patent Citations (2)
Title |
---|
See also references of EP2647636A4 |
SHREDER K.R. ET AL.: "Synthesis and optimization of 2-pyridin-3-yl-benzo[d][1,3] oxazin-4-one based inhibitors of human neutrophil elastase", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, 2009, pages 4743 - 4746, XP026419069 * |
Also Published As
Publication number | Publication date |
---|---|
EP2647636A4 (en) | 2014-11-12 |
JPWO2012073508A1 (ja) | 2014-05-19 |
CA2819375A1 (en) | 2012-06-07 |
EP2647636A1 (en) | 2013-10-09 |
US20130317214A1 (en) | 2013-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3200844A1 (en) | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof | |
NO20130663L (no) | Metode for fremstilling av aminokrotonylforbindelser | |
CN102143964A (zh) | 制备腺嘌呤化合物的方法 | |
ES2879294T3 (es) | Formas polimórficas de Belinostat y procesos para la preparación de las mismas | |
BG65855B1 (bg) | 5-хлоро-3-(4-метансулфонилфенил)-6'-метил-[2,3'] бипиридинил в чиста кристална форма и метод за синтез | |
CN105753840A (zh) | 一种达比加群酯中间体的合成方法 | |
CN104736540B (zh) | 培美曲塞及其赖氨酸盐的制备方法 | |
CN102796079A (zh) | 一种甲磺酸氟马替尼的制备方法 | |
WO2011036895A1 (ja) | マレイン酸塩およびその結晶 | |
CN104628679A (zh) | Bitopertin的新合成方法及其中间体 | |
WO2012073508A1 (ja) | 湿潤結晶を使用したマレイン酸塩の製造方法 | |
ITFI990169A1 (it) | Analoghi di ceramidi, processo per la loro preparazione e loro uso come antitumorali. | |
KR101247137B1 (ko) | N-[o-(p-피발로일옥시벤젠술포닐아미노)벤조일]글리신의 신규 제조 방법 및 그 모노나트륨염ㆍ4 수화물의 동결 건조 제제의 제조 방법 | |
JP5743474B2 (ja) | 4−アミノ−5−クロロ−2−エトキシ−n−〔[4−(4−フルオロベンジル)−2−モルホリニル]メチル〕ベンズアミドクエン酸塩2水和物の製造方法 | |
US9834540B2 (en) | Omeprazole Sodium semihydrate and preparation method thereof | |
KR101278359B1 (ko) | Npyy5 수용체 길항 작용을 갖는 화합물의 제조 방법 및 유용한 결정 | |
WO2017193913A1 (zh) | 一种福沙匹坦磷酸酯中间体及其制备方法 | |
JPWO2012073506A1 (ja) | 安定な合成中間体およびその製造方法 | |
WO2023246807A1 (zh) | 杰克替尼二盐酸盐一水合物的制备工艺 | |
CN106432182B (zh) | 特地唑胺中间体的合成方法 | |
KR101366706B1 (ko) | N-[o-(p-피발로일옥시벤젠술포닐아미노)벤조일]글리신의 신규 제조 방법 및 그 모노나트륨염ㆍ4 수화물의 동결 건조 제제의 제조 방법 | |
JP2020040923A (ja) | オルメサルタンメドキソミルの製造方法 | |
JPH03128363A (ja) | ジスルフィド型サイアミン誘導体の製造方法 | |
JPS5865295A (ja) | セフアロスポリン誘導体及びその製造法 | |
JP2003064036A (ja) | S,s−エチレンジアミン−n,n’−ジコハク酸無水物結晶、及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11845985 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2012546703 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2819375 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011845985 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13990380 Country of ref document: US |